Ionis Pharmaceuticals, Inc.
corporate_fare Company Profile
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 43 items for IONS at importance 7 or higher on its 1–10 market-impact scale.
Recent high-impact activity:
- CEO Sells Over $5.2 Million in Company Stock Following Vesting of Performance-Based Units
- Ionis Pharmaceuticals Exceeds TRYNGOLZA Sales, Doubles Peak Sales Guidance to >$2B, and Highlights Strong 2026 Pipeline
- Ionis Partner GSK Reports Positive Phase 3 Results for Bepirovirsen in Chronic Hepatitis B
Financial Snapshot
Fiscal year ended December 31, 2025
Revenue
$943.71M
Net Income
-$381.39M
Diluted EPS
-$2.38
Op. Cash Flow
-$268.58M
Free Cash Flow
-$320.03M
Gross Profit
$927.8M
Operating Income
-$381.68M
Cash & Equivalents
$372.26M
Total Debt
$28.12M
Debt / Equity
0.06×
Net Margin
-40.4%
Shares Outstanding
163.3M sh
Source: 10-K · filed 2026-02-26 · accession 0000874015-26-000115
show_chartPrice Chart
Loading chart...
feed IONS - Filings & News (Page 3)
IONS
Feb 02, 2026, 8:51 PM EST
Price at Filing:
$83.07
Real-time Price:
$26.76
Change:
-$56.31 (-68%)
Market Cap:
$4.427B
IONS
Jan 12, 2026, 7:00 AM EST
Price at Filing:
$80.40
Real-time Price:
$26.76
Change:
-$53.64 (-67%)
Market Cap:
$4.427B
IONS
Jan 07, 2026, 6:02 AM EST
Price at Filing:
$83.06
Real-time Price:
$26.76
Change:
-$56.30 (-68%)
Market Cap:
$4.427B